Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | FLT3 | P36888 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028163 | 0.89 | MET (0.71) | METEGFRPDGFRBKITKDR | |
| SCHEMBL14028165 | 0.88 | MET (0.72) | METFLT3 | |
| SCHEMBL8288971 | 0.86 | MET (0.65) | METKITKDRFLT3 | |
| SCHEMBL14028177 | 0.85 | MET (0.66) | METEGFRPDGFRBKITKDR | |
| SCHEMBL8288965 | 0.84 | MET (0.67) | METKITKDRFLT3 | |
| SCHEMBL4776474 | 0.83 | MET (0.74) | METEGFRPDGFRBKITKDR | |
| SCHEMBL4772466 | 0.83 | MET (0.80) | METKDRFLT3 | |
| SCHEMBL4776906 | 0.83 | MET (0.79) | METKDRFLT3 | |
| SCHEMBL8288045 | 0.83 | MET (0.72) | METEGFRPDGFRBKITKDR | |
| SCHEMBL4772151 | 0.83 | MET (0.72) | METEGFRPDGFRBKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709043-B1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2005058891-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249105-A1 | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases | PHB2, PHB1, TNNT2 | MET 4445/4885EGFR 4814/4885PDGFRB 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.